Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Tag archive for ‘Quick Shot Testosterone’

Antares: Updates on QST and AB Generic to EpiPen; Reiteration of Buy Recommendation (ATRS, Buy, $1.65)

Overview and Investment Opinion In my opinion, Antares is substantially undervalued. My price target is $6 60 $8 in 2018 and the thinking behind this was explained in my April 22 report An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 Antares: An Outstanding Product Pipeline Promises Dramatic Growth Through 2022 (ATRS, Buy, $0.92) The stock […]

Antares: An Update on My Investment Thinking (ATRS, Buy, $1.33)

Investment Thesis This has been a very disappointing year for Antares investors; the stock closed at $2.57 on December 31, 2014 and as of the close on November 5, 2015 has been nearly cut in half to $1.33. The current market capitalization is $200 million. The three key issues dominating the price in 2014 and […]

Antares: One of My Top Stock Picks for 2015 and 2016 (ATRS, Buy, $2.40, For Paid Subscribers)

Introduction to Report One of my assets is also one of my biggest drawbacks. When I am writing on a Company I start out thinking that I have a good understanding of the Company, but inevitably as I dig deeper, I find out that the more information I gather the more questions that arise in […]

Antares Pharmaceuticals: Highlights of Presentation at JP Morgan Conference (ATRS, $2.36. Buy)

Investment Overview Antares has hit a somewhat dis-settling stretch as Otrexup prescriptions have recently flattened and the FDA recommended that additional patients be enrolled in the safety evaluation of the QST phase 3 trial. I see these as typical of issues that always arise with biopharma companies and can be reasonably resolved. I remain confident […]

Antares: Highlights of CEO’s Presentation at Piper Jaffray Conference (ATRS, Buy, $2.46)

Overview I tuned in to the Antares presentation at the Piper Jaffrey conference on December 2, 2014 to listen to what the new CEO Eamonn Hobbs emphasized to investors in a short 15 minute presentation. He spent a lot of the time talking about Quick Shot Testosterone (QST), the new once a week subcutaneous injectable […]

Antares Pharmaceuticals: An Update on Key Issues (ATRS, Buy, $2.14)

Investment Thesis Antares (ATRS) common has been hit with a storm of concerns that has caused the stock to decline from about $4.50 in March of this year to a low of $1.94 in August. This note addresses these issues and how they affect my investment thinking. In almost every investment situation I have been […]